Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma

The main purpose of this study is to determine the safety of combining ipilimumab and nivolumab with hypofractionated radiotherapy to a single tumor in patients with metastatic melanoma. Another purpose of this study is to determine the effect of ipilimumab, nivolumab and hypofractionated radiotherapy on the cancer as compared to ipilimumab and nivolumab.

Trial Details

NCT ID
NCT03646617
Phase
PHASE2
Sponsor
Abramson Cancer Center at Penn Medicine
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Hypofractionated Radiation Therapy (HFRT)
  • Nivolumab
  • Ipilimumab
Locations (sample)
  • Lancaster, Pennsylvania, United States|40.03788,-76.30551
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362
  • Salt Lake City, Utah, United States|40.76078,-111.89105

Key Eligibility Criteria

  • Histologically confirmed metastatic melanoma.
  • Have at least two measurable lesions (including the index lesion) according to RECIST (Response Evaluation Criteria in Solid Tumours)guidelines v1.1.
  • Have an index lesion measuring between 1cm - 7cm that is amenable to hypofractionated radiation therapy (HFRT) at the discretion of the treating ra…
  • Able to tolerate HFRT (e.g. lie flat and hold position for treatment)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →